Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 1.00 |
| ▸ | RAF1 | P04049 | 15/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.85 |
| ▸ | BRAF | P15056 | 1/20 | 0.85 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.85 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL15901815 | 0.99 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| SCHEMBL15901814 | 0.99 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL960093 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29358292 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29515377 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29360048 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL963841 | 0.91 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL963844 | 0.91 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL959675 | 0.91 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL959677 | 0.91 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | claimed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | claimed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | claimed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | claimed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | claimed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | claimed |
| WO-2023211812-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-2754654-B1 | METHOD FOR PRODUCING COUMARIN DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9133174-B2 | Method for producing coumarin derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20140213786-A1 | Method for Producing Coumarin Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213786-A1 | Method for Producing Coumarin Derivative | CYP3A7, CYP2B6, CYP7A1 | MAP2K1 2570/4885RAF1 689/4885CYP2C9 27/4885 |
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | MAP2K1 1179/4885RAF1 1656/4885CYP2C9 2989/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | MAP2K1 3163/4885RAF1 438/4885CYP2C9 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.